CN115867571A - 高唾液酸化免疫球蛋白 - Google Patents

高唾液酸化免疫球蛋白 Download PDF

Info

Publication number
CN115867571A
CN115867571A CN202180036166.7A CN202180036166A CN115867571A CN 115867571 A CN115867571 A CN 115867571A CN 202180036166 A CN202180036166 A CN 202180036166A CN 115867571 A CN115867571 A CN 115867571A
Authority
CN
China
Prior art keywords
reaction mixture
igg
hsigg
sialylation
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036166.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·谢克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN115867571A publication Critical patent/CN115867571A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202180036166.7A 2020-05-19 2021-05-19 高唾液酸化免疫球蛋白 Pending CN115867571A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063026826P 2020-05-19 2020-05-19
US63/026826 2020-05-19
US202063108741P 2020-11-02 2020-11-02
US63/108741 2020-11-02
PCT/US2021/033150 WO2021236765A1 (en) 2020-05-19 2021-05-19 Hyper-sialylated immunoglobulin

Publications (1)

Publication Number Publication Date
CN115867571A true CN115867571A (zh) 2023-03-28

Family

ID=78708031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036166.7A Pending CN115867571A (zh) 2020-05-19 2021-05-19 高唾液酸化免疫球蛋白

Country Status (11)

Country Link
US (1) US20230192814A1 (https=)
EP (1) EP4153622A4 (https=)
JP (1) JP7835691B2 (https=)
KR (1) KR20230012576A (https=)
CN (1) CN115867571A (https=)
AU (1) AU2021275115A1 (https=)
BR (1) BR112022023334A2 (https=)
CA (1) CA3182136A1 (https=)
CO (1) CO2022016670A2 (https=)
MX (1) MX2022014525A (https=)
WO (1) WO2021236765A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CA3174533A1 (en) * 2020-03-05 2021-09-10 Momenta Pharmaceuticals, Inc. Methods of making hyper-sialylated immunoglobulin
WO2026014960A1 (ko) * 2024-07-11 2026-01-15 건국대학교 산학협력단 인간으로부터 분리한 형질세포들을 이용한 α-2,6-시알산화 면역글로불린의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613705A (zh) * 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
US20100240871A1 (en) * 2008-10-29 2010-09-23 Raju T Shantha Galactose Alpha(1-3) Galactose Compositions
US20160108450A1 (en) * 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
CN110100007A (zh) * 2016-12-21 2019-08-06 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
WO2020077298A1 (en) * 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821482A1 (en) * 2013-07-05 2015-01-07 Roche Diagniostics GmbH N-terminally truncated glycosyltransferases
JP7398002B2 (ja) 2020-02-14 2023-12-13 北京小米移動軟件有限公司 フィードバック方式の指示及び決定方法、装置、記憶媒体
KR20230012560A (ko) 2020-05-19 2023-01-26 모멘타 파머슈티컬스 인코포레이티드 과시알화된 IgG의 제조 및 정제
JP2023538400A (ja) * 2020-08-21 2023-09-07 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化免疫グロブリン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613705A (zh) * 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
US20100240871A1 (en) * 2008-10-29 2010-09-23 Raju T Shantha Galactose Alpha(1-3) Galactose Compositions
US20160108450A1 (en) * 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
CN110100007A (zh) * 2016-12-21 2019-08-06 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
WO2020077298A1 (en) * 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAM W BARB等: "NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation", BIOCHEMISTRY, vol. 51, no. 22, 22 May 2012 (2012-05-22), pages 4618 - 4626, XP055956085, DOI: 10.1021/bi300319q *
NATHANIEL WASHBURN等: "Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity", PROC NATL ACAD SCI USA, vol. 112, no. 11, 2 March 2015 (2015-03-02), pages 1297, XP093155012, DOI: 10.1073/pnas.1422481112 *

Also Published As

Publication number Publication date
CO2022016670A2 (es) 2022-11-29
US20230192814A1 (en) 2023-06-22
KR20230012576A (ko) 2023-01-26
BR112022023334A2 (pt) 2022-12-20
CA3182136A1 (en) 2021-11-25
AU2021275115A1 (en) 2022-11-10
WO2021236765A1 (en) 2021-11-25
JP2023526421A (ja) 2023-06-21
MX2022014525A (es) 2022-12-13
EP4153622A4 (en) 2024-06-12
JP7835691B2 (ja) 2026-03-25
EP4153622A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
CN115867571A (zh) 高唾液酸化免疫球蛋白
US20250195643A1 (en) Treatment with highly siaylated igg compositions
Raju et al. Diversity in structure and functions of antibody sialylation in the Fc
US20230357813A1 (en) Hypersialylated immunoglobulin
Guo et al. Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides
US20230303984A1 (en) Enzymes for Sialylation of Glycans
US20230374062A1 (en) Methods of making hyper-sialylated immunoglobulin
ES2805964T3 (es) Composiciones de galactosa alfa (1-3) galactosa
US20230193339A1 (en) Preparation and Purification of Hypersialylated IGG
RU2844159C1 (ru) Получение и очистка гиперсиалилированного igg
RU2847105C1 (ru) Способы получения гиперсиалилированного иммуноглобулина
RU2849059C1 (ru) Ферменты для сиалилирования гликанов
EP4248218A1 (en) Sialylated glycoproteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination